SCHEMBL20069749

SCHEMBL20069749

CN1CCC(CO)(NC(=O)c2c(F)cccc2F)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.43
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 1/20 0.40
NR3C1 P04150 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
DPP4 P27487 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HCN1 O60741 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
SLC6A9 P48067 3/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147549 0.86 RET (0.42) RETSLC6A9
SCHEMBL25503639 0.83 RET (0.44) RETSLC6A9
SCHEMBL20068928 0.82 MAPK1 (0.43) RETALDH1A1MAPK1KDM4EGAA
SCHEMBL20069182 0.81 RET (0.48) RET
SCHEMBL20069736 0.77 ALDH1A1 (0.42) RETALDH1A1MAPK1KDM4EGAA
SCHEMBL20069768 0.75 RET (0.42) RETALDH1A1MAPK1KDM4EGAA
SCHEMBL20069735 0.74 RET (0.49) RETALDH1A1GAAMAPT
SCHEMBL20069179 0.71 RET (0.48) RET
SCHEMBL7400386 0.71 CYP1A2 (0.34) KDM4E
SCHEMBL20206040 0.70 DPP4 (0.43) RETALDH1A1DPP4L3MBTL1SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885ALDH1A1 2547/4885MAPK1 65/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885ALDH1A1 2547/4885MAPK1 65/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885ALDH1A1 2547/4885MAPK1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.